Clinical Trials Browser

OTHER × Pemetrexed × 30 days × Clear all

NCT06538038 2026-03-16

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05689671 2026-03-10

ANTELOPE

Phase 4 Active not recruiting

Non-Small Cell Lung Cancer Metastatic

NCT04253964 2026-03-06

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Phase 2 Recruiting

Neoplasms, Recurrence

NCT06663306 2026-03-02

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2 Recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

Lung Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Phase 2 Not yet recruiting

Lung Diseases, Interstitial